Suppr超能文献

2017年中国河南省结直肠癌的发病率和死亡率以及2010年至2017年的时间趋势:一项基于人群的登记研究。

Incidence and mortality of colorectal cancer in 2017 and the time-trend from 2010 to 2017 in Henan province, China: a population-based registry study.

作者信息

Zhang Jian-Gong, Liu Yin, Chen Qiong, Xu Hui-Fang, Wang Xiao-Yang, Guo Lan-Wei, Kang Rui-Hua, Zhang Lu-Yao, Wang Hong, Zhang Shao-Kai

机构信息

Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.

出版信息

Ann Transl Med. 2022 Aug;10(16):878. doi: 10.21037/atm-22-3788.

Abstract

BACKGROUND

Henan province is an area with a serious disease burden of colorectal cancer (CRC) in China. Understanding the current incidence and mortality and the time-trend is critical to formulate and optimize prevention and control strategies for CRC. However, the current incidence and mortality and time-trend of CRC in Henan province, China have not been reported.

METHODS

CRC data was got from the Henan Provincial Central Cancer Registry of China in which the data was submitted from local cancer registries. Combined with the census data, the incidence, mortality, proportion, age-standardized rate by Chinese population (ASRC), age-standardized rate by world population (ASRW), and cumulative incidence and mortality (0-74 years old) of CRC by urban and rural population, gender, and age groups were estimated. The average annual percentage change (AAPC) and its 95% confidence interval (CI) of ASRC from 2010 to 2017 were analyzed.

RESULTS

In 2017, it was estimated that there were 20,275 new cases and 10,046 deaths of CRC in Henan province. The crude incidence was 18.73/100,000, with an age-standardized incidence rate by Chinese population (ASIRC) of 13.97/100,000 and age-standardized mortality rate by world population (ASIRW) of 13.78/100,000. The cumulative incidence was 1.66%. The mortality rate was 9.28/100,000, with an age-standardized mortality rate by Chinese population (ASMRC) of 6.49/100,000 and an age-standardized mortality rate by world population (ASMRW) of 6.45/100,000. The cumulative mortality rate was 0.69%. The ASIRC and ASMRC were higher in urban areas (15.89/100,000, 7.19/100,000) than in rural areas (13.13/100,000, 6.20/100,000), and higher in males (15.53/100,000, 7.44/100,000) than in females (12.48/100,000, 5.66/100,000). The age-specific incidence reached the peak at age of 80-84, and the age-specific mortality reached the peak at age 85. From 2010 to 2017, the overall ASIRC and ASMRC showed a steady trend (P>0.05), while an upward trend was observed in the mortality rate in urban males (AAPC =3.4, 95% CI: 0.2-6.7, P=0.040).

CONCLUSIONS

The incidence and mortality of CRC were high in Henan province, and higher in urban areas and males. It is critical to strengthen the prevention and control of CRC, carry out targeted intervention, and promote screening and early diagnosis and treatment, particularly among urban areas and males.

摘要

背景

河南省是中国结直肠癌(CRC)疾病负担较重的地区。了解当前的发病率、死亡率及时间趋势对于制定和优化CRC防控策略至关重要。然而,中国河南省CRC的当前发病率、死亡率及时间趋势尚未见报道。

方法

CRC数据来自中国河南省肿瘤登记中心,该数据由当地癌症登记处提交。结合人口普查数据,估算了城乡人口、性别和年龄组的CRC发病率、死亡率、比例、中国人群年龄标准化率(ASRC)、世界人群年龄标准化率(ASRW)以及累积发病率和死亡率(0至74岁)。分析了2010年至2017年ASRC的年均变化百分比(AAPC)及其95%置信区间(CI)。

结果

2017年,估计河南省有20275例CRC新发病例和10046例死亡病例。粗发病率为18.73/10万,中国人群年龄标准化发病率(ASIRC)为13.97/10万,世界人群年龄标准化死亡率(ASIRW)为13.78/10万。累积发病率为1.66%。死亡率为9.28/10万,中国人群年龄标准化死亡率(ASMRC)为6.49/10万,世界人群年龄标准化死亡率(ASMRW)为6.45/10万。累积死亡率为0.69%。ASIRC和ASMRC在城市地区(分别为15.89/10万、7.19/10万)高于农村地区(分别为13.13/10万、6.20/10万),男性(分别为15.53/10万、7.44/10万)高于女性(分别为12.48/10万、5.66/10万)。年龄别发病率在80 - 84岁达到峰值,年龄别死亡率在85岁达到峰值。2010年至2017年,总体ASIRC和ASMRC呈稳定趋势(P>0.05),而城市男性死亡率呈上升趋势(AAPC = 3.4,95% CI:0.2 - 6.7,P = 0.040)。

结论

河南省CRC的发病率和死亡率较高,城市地区和男性更高。加强CRC的预防和控制、开展针对性干预以及促进筛查和早期诊断治疗至关重要,特别是在城市地区和男性中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4947/9469152/64210d9994fa/atm-10-16-878-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验